

Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA

London, 28 August 2024 – In our ongoing series exploring Hikma Pharmaceutical's role as the partner of choice in the MENA region, this second instalment highlights how since our founding, Hikma has been dedicated to addressing the high unmet healthcare needs in the Middle East and North Africa (MENA). Our journey has evolved into a story of expansive growth and innovation, all aimed at improving patient access to high-quality, world-class medicines. Now, as the second-largest pharmaceutical company in MENA by sales¹, Hikma's unique position stems from our deep understanding of local healthcare landscapes combined with our global expertise. Our presence across 17 markets gives us an unparalleled footprint that allows us to support the region's healthcare needs.

A rapidly growing population, increasing prevalence of cancer and chronic diseases, and disparities in healthcare access across the region continue to drive demand for high-quality, differentiated and innovative healthcare solutions across the MENA region. Hikma has been playing an important part in addressing these issues for over four decades, leveraging our extensive local footprint and deep understanding of the regional healthcare landscape. Hikma's commitment to bringing better health within reach is evident in our continuous efforts to enhance our increasingly diverse product portfolio and pipeline.

Our focus on expanding our portfolio, particularly in oncology and immunology, is responding to the region's evolving needs. We work with global innovators to bring treatments and wider healthcare solutions to MENA like Guardant Health for cancer diagnostics, Rakuten Medical for innovative cancer treatments and Junshi Biosciences for an innovative anti-PD-1 monoclonal antibody. These partnerships, along with the work of our R&D teams, are improving cancer care in the region. We've been investing in building dedicated manufacturing capacity for oncology products in MENA, particularly in countries that do not have direct access to these medications. In Algeria, we were the first local manufacturer of oral oncology medications. We also have the only local oral oncology plant in Egypt. Our API plant in Jordan, one of the first established in the region with US FDA approval, supports our oncology efforts and gives us a competitive edge in meeting patient needs.

Our longstanding partnership with Celltrion Healthcare continues to grow and develop our biosimilar portfolio, complementing our strategy of building a diverse range of differentiated products for an evolving sector poised for substantial growth in the region.

Our local manufacturing efforts are also a testament to the power of global expertise applied to meeting local needs. Through our 20 manufacturing plants in the region, with US FDA and EMA inspected facilities in Jordan and the Kingdom of Saudi Arabia (KSA), we ensure high international standards. We are currently expanding our manufacturing capabilities further with two nearly completed sterile injectable plants in Algeria and Morocco and plans underway for a new manufacturing complex in Saudi Arabia. This expansion is aligned with our aim to increase access to essential medicines accommodating local needs and/or requirements across our markets.

Being the first pharmaceutical company to have US FDA-inspected facilities in the region, we have set a benchmark for higher quality manufacturing standards. However, our commitment to the region goes beyond manufacturing. We have been dedicated to bringing cutting-edge technology and innovation in all aspects to the region from the beginning. For example, we were the first company to launch innovative products for organ transplants, we helped shape regulatory guidelines that increase access to bio-better products and innovative biologics, and we were the first company to launch new oncology solutions.

¹ IQVIA MIDAS Pharma Index MAT May-2024. Does not include hospital or tender business



Looking ahead, we are well-positioned to provide broader healthcare solutions by leveraging our unique operating model in the region. For multinational companies who are looking to make a meaningful impact in MENA healthcare, Hikma offers more than just market access. Supported by our highly experienced team in MENA, ranging from regulatory to medical to market access to compliance to commercial etc., our extensive operational reach distinguishes us in the region. All of this coupled with our track record of having successful long-term partnerships with multinational companies establishes our position as the partner of choice. We are proud to be able to offer a partnership built on deep regional knowledge, global expertise, and a shared vision of shaping a healthier world.

As we continue to invest, innovate, and evolve, together, we can play an important part in transforming the next chapter in MENA's healthcare story to improve patient outcomes across the region.

-- ENDS --

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2024 Hikma Pharmaceuticals PLC. All rights reserved.

Forward-looking statements

Hikma cautions shareholders that any forward-looking statements or projections made by Hikma, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those risk factors described in the "Principal risks and uncertainties" section in Hikma's latest Annual Report. Where included, such statements have been made by or on behalf of Hikma in good faith based upon the knowledge and information available to the Directors on the date of this announcement. Accordingly, no assurance can be given that any particular expectation will be met and Hikma's shareholders are cautioned not to place undue reliance on any forward-looking statements. Other than in accordance with its legal or regulatory obligations (including under the UK Market Abuse Regulation and the UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), Hikma does not undertake to update any forward-looking statements contained in this announcement to reflect any changes in events, conditions or circumstances on which any such statement is based or to correct any inaccuracies which may become apparent in any such forward-looking statements.